EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-COPD-06(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under Indian medical guidelines, stem cell therapy for Chronic Lung Diseases (COPD / Pulmonary Fibrosis) is strictly investigational and administered under active Institutional Ethics Committee (IEC) oversight.
Pathophysiology & Disease Context:
Chronic lung diseases—such as Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF)—cause progressive alveolar destruction, parenchymal scarring, and chronic airflow limitation.
Biological Rationale & Paracrine Action:
Explores the anti-inflammatory, immunomodulatory, and antifibrotic paracrine activity of clinical-grade umbilical cord-derived mesenchymal stem cells (UC-MSCs) or autologous bone marrow mononuclear cells (BMMNCs) to attenuate alveolar microvascular inflammation, downregulate TGF-$\beta$ fibrotic signaling, and support respiratory functional capacity alongside standard pharmacological therapy.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Patients with diagnosed moderate-to-severe stable COPD (GOLD Stages II–III) or mild-to-moderate Idiopathic Pulmonary Fibrosis (IPF) showing clinical decline despite standard inhaler/antifibrotic therapy.
Mandatory Pre-Procedure Diagnostics:
High-Resolution Computed Tomography (HRCT) of the chest (< 3 months old), post-bronchodilator Pulmonary Function Test (PFT: FEV1, FVC, DLCO), 6-Minute Walk Test (6MWT), 2D-ECHO (screening for pulmonary arterial hypertension), and arterial blood gas (ABG).
Strict Safety Exclusion Parameters:
Active acute respiratory exacerbation/infection, severe pulmonary hypertension (mPAP > 45 mmHg), oxygen dependence requiring high-flow mechanical ventilation, active or historical lung malignancy, or current active cigarette smoking (must be cessation-verified for ≥ 6 months).
Triage Protocol & Multi-Specialty Clearance:
Pulmonary board evaluation of diagnostic imaging and spirometry prior to issuing medical visa clearance.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Exercise Tolerance: Modest improvements in 6-minute walk distance (6MWD) and stamina for daily activities.
- Dyspnea Relief: Reduction in baseline shortness of breath (mMRC dyspnea scale) and chest tightness.
- Exacerbation Frequency: Potential reduction in the frequency and severity of acute inflammatory flare-ups.
- Quality of Life: Improved St. George's Respiratory Questionnaire (SGRQ) scores reflecting easier mobility and reduced fatigue.
Documented Procedural Risks & Limits:
- Transient post-infusion pyrexia (low-grade fever), mild fatigue, or localized IV site soreness (typically resolving within 24–48 hours).
- Potential for mild, temporary bronchospasm or transient oxygen desaturation during infusion (managed via continuous monitoring and supplemental $O_2$).
- No Guaranteed Tissue Reversal: Cellular therapy cannot replace extensively destroyed emphysematous bullae or reverse end-stage "honeycomb" fibrotic scarring.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Hospital Accreditation
Delivered in tertiary care medical complexes accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH) and JCI.
Multidisciplinary Board
Dedicated oversight by interventional pulmonologists, critical care specialists, and pulmonary rehabilitation physiotherapists.
Regulatory Governance
Protocols monitored by an active Institutional Ethics Committee (IEC) registered with the Department of Health Research (DHR) / CDSCO.
Ethical Triage
Patients are accepted only when diagnostic data indicates potential adjunctive utility without compromising primary medical care.
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Teleconsultation
Video consultation with lead pulmonologists to review HRCT scans, DLCO measurements, and travel fitness.
Travel & Visa Facilitation
Priority Government of India Medical Visa (MED) and Medical Attendant (MED-X) invitation documentation.
Dedicated Case Liaison
Single multilingual liaison managing airport transfers, scheduling, and hospital logistics.
Remote Follow-Up Program
Scheduled telemedicine reviews at Months 1, 3, 6, and 12, coordinating PFT metrics directly with the patient's home chest physician.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Climate-Controlled Transfers
Private, air-conditioned vehicle pick-up and drop-off equipped with portable oxygen concentrator support if required.
Clean-Air Accommodations
Private hospital suites and partner serviced apartments equipped with medical-grade HEPA air purifiers, attendant bedding, and barrier-free bathrooms.
Specialized Care Amenities
Tailored nutritional planning (high-protein, low-carbohydrate pulmonary diets), local SIM card assistance, and 24/7 access to emergency respiratory care desks.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 4 to 5 days structured in-hospital observation pathway.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Chronic Lung Diseases (COPD / Pulmonary Fibrosis)
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Multicenter Placebo-Controlled Trial of Allogeneic MSCs in Moderate-to-Severe COPD
Weiss, D. J., Casaburi, R., Flannery, R., LeRoux-Stewart, M., Liu, J. Z., & Tashkin, D. P. (2013). A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest, 143(6), 1590–1598. Clinical Significance: In a multicenter, double-blind, placebo-controlled Phase II trial across 62 patients receiving monthly intravenous infusions of allogeneic bone marrow-derived MSCs (Prochymal), the protocol demonstrated safety and reduced circulating C-reactive protein (CRP) in patients with elevated baseline systemic inflammation, though it did not show significant differences in spirometry ($FEV_1$) or 6-minute walk distance.
First-in-Human Safety Trial of Allogeneic MSCs in Idiopathic Pulmonary Fibrosis (AETHER Trial)
Glassberg, M. K., Minkove, J., Bonser, L. R., et al. (2017). Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial. Chest, 151(5), 971–981. Clinical Significance: Evaluated single-dose escalating intravenous infusions of allogeneic bone marrow-derived MSCs ($20\times 10^6$, $100\times 10^6$, or $200\times 10^6$ cells) in 9 mild-to-moderate IPF patients. Established clinical safety with no non-hematologic dose-limiting toxicities, acute pulmonary exacerbations, or treatment-related deaths at 60 weeks post-infusion.
High-Cumulative-Dose Allogeneic MSC Therapy in Rapidly Declining IPF
Averyanov, A., Koroleva, I., Konoplyannikov, M., Revkova, V., Lesnyak, V., Kalsin, V., Danilevskaya, O., Gao, Z., & Kotov, S. (2020). First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Translational Medicine, 9(1), 6–16. Clinical Significance: Evaluated repeat high-cumulative doses of allogeneic bone marrow MSCs ($2\times 10^8$ cells per infusion every 3 months, cumulative $1.6\times 10^9$ cells) in 20 patients with rapidly progressive IPF. The cell-treated cohort demonstrated preservation of forced vital capacity ($FVC$) and diffusion capacity ($DLCO$) alongside improved 6-minute walk distance compared to historical and untreated controls.
Autologous Bone Marrow Mononuclear Cell Clinical Trial in Severe COPD/Emphysema
Ribeiro-Paes, J. T., Bilaqui, A., Greco, O. T., Ruiz, M. A., Paschoal, V. D., Stessuk, T., de Oliveira, C. A., & Faria, C. A. (2011). Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema. International Journal of Chronic Obstructive Pulmonary Disease, 6, 63–71. Clinical Significance: Evaluated systemic autologous bone marrow mononuclear cell (BMMNC) infusion in advanced COPD (GOLD Stage IV). Documented safety, tolerability, and modest improvements in clinical quality-of-life scores without serious adverse respiratory events, serving as a baseline human study for autologous bone marrow cell delivery in pulmonary emphysema.
Statutory Notice & Mandatory Regulatory Disclosure:
Under the National Guidelines for Stem Cell Research jointly formulated by the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT), as well as directives from the National Medical Commission (NMC), stem cell therapy for chronic lung diseases (including COPD and pulmonary fibrosis) is classified as investigational and experimental. It is not recognized by the Central Drugs Standard Control Organisation (CDSCO) as a standard commercial treatment or cure. It is administered strictly within ethics-committee-approved clinical research protocols. Patients are advised never to discontinue or reduce their prescribed inhalers, antifibrotics, pulmonary rehab, or home oxygen therapy.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.